Loading
companiesCompany
Aulos Bioscience
Aulos Bioscience is a Californian biotech whose antibody AU-007 binds interleukin-2 so that the body's own cytokine expands cancer-killing cells without feeding the regulatory cells that dampen immunity.
Overview
Aulos Bioscience was founded by Apple Tree Partners and Biolojic Design around a computationally designed antibody, AU-007, that binds interleukin-2 at the CD25 epitope. This redirects endogenous and administered IL-2 towards CD8 T cells and natural killer cells and away from regulatory T cells. AU-007 is in phase 1/2 trials alone and with low-dose aldesleukin in solid tumours.
Headquarters
Larkspur, California, US
Scorecard
All companies#476of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Founded
2020
Phase 2Monoclonal antibody
AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.